How many 8-K filings has Matinas Biopharma Holdings, Inc. filed?

Matinas Biopharma Holdings, Inc. (MTNB) has 28 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Matinas Biopharma Holdings, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Matinas Biopharma Holdings, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Matinas Biopharma Holdings, Inc. (MTNB) — 8-K Filings

All 8-K filings from Matinas Biopharma Holdings, Inc.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

Matinas BioPharma Files 8-K: Officer/Director Changes & Financials — Dec 12, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. filed an 8-K on December 12, 2025, reporting on the departure of directors or certain officers, election of directors, appointm
Matinas BioPharma Announces Executive and Director Changes — Nov 21, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. announced on November 18, 2025, changes in its board and executive compensation. Specifically, the company reported the departu
Matinas BioPharma Files 8-K: Material Agreement & Equity Sales — Aug 18, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. filed an 8-K on August 18, 2025, reporting on events that occurred on August 15, 2025. The filing indicates the entry into a ma
Matinas BioPharma Files 8-K for Bylaws and Financials — Aug 6, 2025 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on August 6, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The f
Matinas BioPharma Announces Director Changes and Executive Compensation — Jun 23, 2025 Risk: medium
On June 23, 2025, Matinas BioPharma Holdings, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Terry L
Matinas BioPharma Files 8-K on Governance and Shareholder Matters — May 2, 2025 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on May 2, 2025, reporting on several events as of April 30, 2025. These include material modifications to security
Matinas BioPharma Files 8-K on Equity Sales — Apr 8, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. filed an 8-K on April 8, 2025, reporting on unregistered sales of equity securities and other events. The filing details the co
Matinas BioPharma Files 8-K on Shareholder Vote — Apr 4, 2025 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on April 4, 2025, reporting on the submission of matters to a vote of security holders. The filing does not contai
Matinas BioPharma Appoints New Directors, Updates Executive Contracts — Mar 14, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. announced on March 13, 2025, changes in its board of directors and executive compensation. Specifically, the company elected tw
Matinas BioPharma Announces Board & Officer Changes — Mar 11, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. announced on March 11, 2025, changes related to its board of directors and certain officers, including the departure of directo
Matinas BioPharma Files 8-K: Agreements, Equity Sales, Officer Changes — Feb 13, 2025 Risk: medium
On February 13, 2025, Matinas BioPharma Holdings, Inc. filed an 8-K report detailing several significant events. These include entering into a material definiti
Matinas BioPharma Announces CMO Departure, Director Changes — Feb 11, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. announced on February 5, 2025, the departure of Dr. Terry H. Liang from his role as Chief Medical Officer. The company also rep
Matinas BioPharma CMO Departs, New Interim Appointed — Feb 7, 2025 Risk: medium
On February 5, 2025, Matinas BioPharma Holdings, Inc. reported the departure of Dr. Terry H. Liang from his role as Chief Medical Officer. The company also anno
Matinas BioPharma Announces Board and Executive Changes — Jan 24, 2025 Risk: medium
Matinas BioPharma Holdings, Inc. announced on January 21, 2025, changes in its board of directors and executive compensation. The filing details the departure o
Matinas BioPharma Files 8-K on Listing Rule Concerns — Jan 10, 2025 Risk: high
Matinas BioPharma Holdings, Inc. filed an 8-K on January 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, a
Matinas BioPharma Appoints New Chief Medical Officer — Nov 27, 2024 Risk: medium
Matinas BioPharma Holdings, Inc. announced on November 27, 2024, the appointment of Dr. Terry L. Horgan as Chief Medical Officer. Dr. Horgan brings extensive ex
Matinas BioPharma Reports 8-K Filing with Key Corporate Updates — Oct 31, 2024 Risk: medium
Matinas BioPharma Holdings, Inc. filed an 8-K on October 31, 2024, reporting several key events. These include costs associated with exit or disposal activities
Matinas BioPharma Announces Executive and Board Changes — Oct 24, 2024 Risk: medium
Matinas BioPharma Holdings, Inc. announced on October 23, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Terry L. Horgan
Matinas BioPharma Files 8-K on Security Holder Rights — Sep 3, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on August 30, 2024, reporting material modifications to security holder rights and amendments to its articles of i
Matinas BioPharma to be Acquired by New Mountain Capital — Aug 28, 2024 Risk: medium
Matinas BioPharma Holdings, Inc. announced on August 27, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of the private equ
Matinas BioPharma to be Acquired by 3D Medicines — Aug 20, 2024 Risk: medium
Matinas BioPharma Holdings, Inc. announced on August 20, 2024, that it has entered into a definitive agreement to be acquired by 3D Medicines Inc. for approxima
Matinas BioPharma Files 8-K: Material Agreement — Apr 5, 2024 Risk: medium
On April 2, 2024, Matinas BioPharma Holdings, Inc. entered into a material definitive agreement. The company also disclosed information related to Regulation FD
Matinas BioPharma Files 8-K for Disclosure and Exhibits — Mar 28, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on March 28, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does
Matinas BioPharma Files 8-K — Mar 25, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on March 25, 2024, reporting on other events and financial statements. The filing does not contain specific financ
Matinas BioPharma Files 8-K — Mar 22, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on March 22, 2024, to report other events and financial statements. The filing does not contain specific details a
Matinas BioPharma Files Routine 8-K — Feb 26, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on February 26, 2024, to disclose general information under Regulation FD Disclosure, Other Events, and Financial
Matinas BioPharma Files 8-K on Current Events — Feb 20, 2024 Risk: low
Matinas BioPharma Holdings, Inc. filed an 8-K on February 20, 2024, to report a current event. The filing indicates the company's business address is 1545 Route
Matinas BioPharma Files 8-K for Reg FD Disclosure on Jan 9, 2024 — Jan 9, 2024
Matinas BioPharma Holdings, Inc. filed an 8-K on January 9, 2024, primarily for Regulation FD Disclosure and to include financial statements and exhibits. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX